We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.

September 3, 2026 Ref: NEPHROPLUS/SE/83 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme 2026 Dear Sir/Madam, Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Nomination and Remuneration Committee (“NRC”) of the Board of Directors of Nephrocare Health Services Limited (“Company”), by way of resolution(s) passed by circulation on September 3, 2026, has approved the grant of an aggregate of 4,01,362 (Four Lakh One Thousand Three Hundred and Sixty-Two) Employee Stock Options (“Options”) under the NephroPlus Employee Stock Option Scheme 2026 (“ESOP 2026” or “Scheme”) to eligible employees identified by the NRC. Each Option, upon vesting and exercise in accordance with the terms and conditions of ESOP 2026 and the respective Grant Letters, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- (Rupees Two only) each. The Options have been granted at an exercise price of ₹230/- (Rupees Two Hundred and Thirty only) per Option and shall vest subject to fulfilment of the applicable vesting conditions, as specified in the respective Grant Letters. The relevant details with respect to above item as required under SEBI Listing Regulations read with SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026 is enclosed as Annexure I. The aforesaid information is also being made available on the website of the Company at www.nephroplus.com. For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Encl.: As above Annexure I Details of grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme 2026 Sr. Particulars Details 1 Brief details of Options The NRC has approved the grant of an aggregate of 4,01,362 granted (Four Lakh One Thousand Three Hundred and Sixty-Two) Employee Stock Options (“Options”) under ESOP 2026 to eligible employees of the Company. Each Option, upon vesting and exercise, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- each. 2 Whether the Scheme is in Yes. ESOP 2026 is in compliance with the SEBI (Share Based terms of the SEBI (Share Employee Benefits and Sweat Equity) Regulations, 2021 (“SEBI Based Employee Benefits SBEB Regulations”). and Sweat Equity) Regulations, 2021 3 Total number of shares 4,01,362 equity shares of face value of ₹2/- each may arise upon covered by these Options exercise of the Options, assuming vesting and exercise of all Options granted. Each Option is convertible into one equity share of the Company. 4 Pricing formula / Exercise The Options have been granted at an Exercise Price of ₹230/- Price (Rupees Two Hundred and Thirty only) per Option, as determined by the NRC in accordance with ESOP 2026 and specified in the respective Grant Letters. 5 Options vested Not applicable at this stage. The Options granted are subject to a minimum vesting period of one year from the Grant Date and fulfilment of the applicable Vesting Conditions and other terms specified in the respective Grant Letters. 6 Time within which The Vested Options may be exercised within a maximum period Options may be exercised of 5 (five) years from the date of each respective Vesting, or within such shorter period as may be prescribed by the Nomination and Remuneration Committee and specified in the relevant Grant Letter, subject to the terms and conditions of ESOP 2026. In the event of cessation of employment/service or other specified events, the Exercise Period shall be governed by the applicable provisions of ESOP 2026. 7 Options exercised Not applicable at this stage. 8 Money realised by Not applicable at this stage. exercise of Options 9 Total number of shares Not applicable at this stage. arising as a result of exercise of Options 10 Options lapsed Not applicable at this stage. 11 Variation of terms of Not applicable at this stage. Options 12 Brief details of significant The Options shall be governed by ESOP 2026, the respective terms Grant Letters and the SEBI SBEB Regulations, and shall vest subject to the fulfilment of the applicable vesting conditions as approved by the Nomination and Remuneration Committee (“NRC”) and set out in the respective Grant Letters, as accepted by the Option Grantees. The Options shall, in all circumstances, be subject to the applicable minimum vesting period prescribed under ESOP 2026 and applicable law. In the event the applicable vesting conditions are not fulfilled within the period stipulated in the respective Grant Letters, the corresponding unvested Options shall automatically lapse and be returned to the pool under ESOP 2026 for future grants, without requiring any further act, action or approval of the NRC. 13 Subsequent changes or Not applicable at this stage. cancellation or exercise of such Options 14 Diluted earnings per Not applicable at this stage. share pursuant to issue of equity shares on exercise of Options